Revolution Medicines Inc. (NASDAQ: RVMD) presented updated Phase 1 clinical data for zoldonrasib in patients with previously treated KRAS G12D ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE